42 results about "Proliferative vitreoretinopathy" patented technology

RNA interference is provided for inhibition of connective tissue growth factor mRNA expression in ocular disorders involving CTGF expression. Ocular disorders involving aberrant CTGF expression include glaucoma, macular degeneration, diabetic retinopathy, choroidal neovascularization, proliferative vitreoretinopathy and wound healing. Such disorders are treated by administering interfering RNAs of the present invention.

Antagonists of cation-independent mannose 6-phosphate / insulin-like growth factor-II receptor are provided for attenuation of CTGF signaling in a method of down-regulation of receptor signaling and downstream decreased signaling of connective tissue growth factor in ocular disorders involving inappropriate CTGF signaling. Ocular disorders involving inappropriate CTGF signaling include ocular hypertension, glaucoma, glaucomatous retinopathy, optic neuropathy, macular degeneration, diabetic retinopathy, choroidal neovascularization, and proliferative vitreoretinopathy, for example. Such disorders are treated by administering antagonists of the present invention.

The invention provides application of lncRNA-MALAT1 in preparing a proliferative vitroretinopathy (PVR) diagnosis reagent. The invention also provides an MALAT1 detection kit for PVR diagnosis. The kit comprises an RNA (ribonucleic acid) extraction system, a reverse transcription reaction system and a PCR (polymerase chain reaction) reaction system. On the basis of real-time fluorescent quantitative PCR, the kit can be used for carrying out PVR early diagnosis by detecting the relative content of MALAT1 in the serum or plasma. The method has the characteristics of small trauma and the like, and is convenient to operate.

The treatment of many ocular disorders is hampered because of poor penetration of systemically administered drugs into the eye. The tight junctional complexes (zonulae occludens) of the retinal pigment epithelium and retinal capillaries are the site of the blood-ocular barrier. This barrier inhibits penetration of substances, including antibiotics, into the vitreous. Over the last 18 years we have evaluated the nontoxic doses of various drugs. These include antibiotics and antifungals for treatment of bacterial and fungal endophthalmitis, antivirals for treatment of viral retinitis (specifically, when medication with these drugs poses the threat of toxicity to other organs). Intravitreal antineoplastic drugs have been studied to prevent cell proliferation in the vitreous cavity after retinal attachment surgery, which can lead to proliferative vitreoretinopathy (PVR). Furthermore, we evaluated the anti-inflammatory action of dexamethasone and cyclosporine A to reduce intraocular inflammation after intraocular surgery or in uveitis. Because these studies had been performed in the presence of the vitreous, which can slow down the diffusion of the drugs toward the retina, it was necessary to reevaluate the concentration of drugs which could be administered intravitreally in the vitrectomized eye. The nontoxic dose of numerous drugs when added to vitrectomy infusion fluid has also been evaluated. Furthermore, the role of vitrectomy in the treatment of bacterial fungal endophthalmitis has been studied and the role of vitrectomy in this ocular disorder is defined.

The invention provides compositions and methods for treatment of proliferative vitreoretinopathy.

A method for preventing and / or treating fibrosis associated with an eye-related disease or disorder includes administering an effective amount of a multikinase inhibitor to a subject in need thereof. The multikinase inhibitor is nintedanib, lenvatinib, a combination thereof, or a salt thereof. The eye-related disease or disorder is corneal transparency, corneal scar formation, secondary cataract formation, glaucoma filtration surgery, ocular surgical procedures and implants, photorefractive keratectomy, laser in situ keratomileusis, formation and contraction of pre- and epiretinal membranes, proliferative vitreoretinopathy, subretinal fibrosis / scarring, retinal gliosis, or formation of choroidal membranes.

The present invention is related to a method for treating an ocular disease, particularly a diabetes related ocular disease, comprising administering to a subject in need thereof an effective amount of a group of compounds having a structure of Formula A1, wherein the ocular disease is selected from the group consisting of proliferative vitreoretinopathy (PVR), uveitis, glaucoma and age related macular degeneration (AMD), and the diabetes related ocular disease is selected from the group consisting of diabetic retinopathy (DR) and diabetic macular edema (DME).

The invention relates to an ophthalmic controlled release system of long-action low molecular heparin which comprises the low molecular heparin as drug and a drug carrier made from synthesized or natural biodegradable high molecular materials and is characterized in that the proportion range of the low molecular heparin and the drug carrier is (1:8) to (5:1); the average molecular mass of the lowmolecular heparin is less than 8000 Dalton; the molecules less than 8000 Dalton, the salt compounds of the low molecular heparin such as sodium salt, calcium salt and kali salt included, take up not less than 60 percent of the total molecules of the low molecular heparin; the synthesized or natural biodegradable high molecular materials are polyglycolic acid and gelatin or bletilia striata gelatinrespectively. The ophthalmic controlled release system of long-action low molecular heparin can effectively inhibit the proliferation and migration of lenticular epithelia and fibroblasts in eyes, reduce fibrinous exudates post operation, alleviate inflammatory reaction post operation and prevent posterior capsular opacification, thereby inhibiting the occurrence of after-cataract; meanwhile, theophthalmic controlled release system of long-action low molecular heparin inhibits the proliferation of retinal pigment epithelium and fibroblasts, thus inhibiting the proliferative vitreoretinopathy(PVR).

The invention discloses the application of circRNA in the preparation of proliferative vitreoretinopathy (PVR) diagnostic reagents. The invention also discloses a circRNA detection kit for PVR diagnosis. The kit mainly includes RNA extraction system, reverse transcription reaction system and PCR reaction system. The relative content of circRNA in vitreous and serum was detected by real-time quantitative PCR technology for early diagnosis of PVR. This method has the characteristics of less trauma, high sensitivity and simple operation.

The invention relates to siRNA interfering with HSPA13 expression and application thereof, in particular to siRNA molecule interfering with HSPA13 expression and application of the siRNA molecule as therapeutic drug for preparing proliferative vitreoretinopathy. The siRNA molecule is adopted to interfere with the expression of HSPA13, realizes the occurrence and development of effective treatmentof PVR from the gene molecule level, and can avoid the risks caused by other treatment methods.

Methods of preventing retinal detachment associated with proliferative vitreoretinopathy are provided by administering agents which antagonize the activity or function of EMP2 to subjects at risk of the detachment.

Glutamate causes migration and proliferation of retinal pigment epithelium and / or glial cells, and glutamate antagonists can prevent, treat or reduce retinal pigment epithelium and / or glial migration and the subsequent development of proliferative vitreoretinopathy. Avoidance or management of proliferative vitreoretinopathy can be achieved by administering to the patient a compound capable of reducing glutamate-induced retinal cell migration in a concentration effective to reduce such migration.